RENEGYRG-RG Pharmaceutical

RG Pharmaceutical-RENEGY is a solution for parenteral (intravenous) formed by a highly stable complex ferric iron (Fe3 +) covered by a structure formed by a high molecular weight carbohydrate (carboxymaltose). Due to the high stability of the complex, the carboxymaltose RENEGY  does not release ionic iron directly into the bloodstream, preventing it from causing cell damage due to oxidative stress in

the body.

After intravenous administration of RENEGY, and incorporation into the plasma, this progressively penetrates in the reticuloendothelial system (RES) from the intravascular compartment, to the resident macrophages of the liver, spleen and bone marrow being phagocytized and deposited in intracellular lysosomes where ferric iron (Fe 3+) is reduced to its ferrous form (Fe 2+) according to the body's requirements. 

Once the ferric iron (Fe 3+) is reduced to ferrous form (Fe 2+) inside the lysosome, it is captured by the divalent metal transporter (by its acronym T1DM), which are in the lysosome membrane and release the iron in the macrophage cytoplasm labile form. And in the macrophage cytoplasm, iron can be grasped by ferroportin for transportation outside the macrophage or ferritin for storage. This process is regulated largely by hepcidin, which allow, in case of decrease in plasma iron concentration, binding of the ferrous iron to ferroportin to be transported through the macrophage membrane and released to the outside.